Pharming celebrates “hae day :-)”
Other updatesPharming Group N.V. today supports “hae-day :-)”, the global awareness day for hereditary angioedema (HAE), a rare life-threatening condition.
Pharming’s Annual General Meeting Webinar: Sign up link / Link voor aanmelden
WebinarsPharming Group N.V. holds it 2020 Annual General Meeting (AGM) on 20 May 2020 at 14:00 CET.
Pharming Group reports financial results for the first quarter of 2020
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2020.
Pharming receives European Commission approval for treatment of acute hereditary angioedema attacks in children with RUCONEST®
Operational updatesPharming Group N.V. announces that it has received formal European Commission approval to treat acute hereditary angioedema (HAE) attacks in children with RUCONEST®. Following the positive opinion and recommendation from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on the extension of the indication for RUCONEST® received on 26 March 2020.
Pharming reports encouraging results from use of RUCONEST® in COVID-19 patients
Operational updatesPharming Group N.V. announces encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.
Pharming Group convenes Annual General Meeting of Shareholders
Financial updatesPharming Group N.V. invites its shareholders to the 2020 Annual General Meeting (AGM) to be held at 14:00 CET on 20 May 2020
Update: Conference Call slides available
Conference attendanceCall slides now available for download.
Publication of Pharming’s 2019 Annual Report
Financial updatesAnnual Report 2019 is available for download on the Pharming website today
CHMP adopts positive opinion for treatment of acute angioedema attacks in children with hereditary angioedema with RUCONEST®
Operational updatesPharming Group N.V. announces the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension of the indication for RUCONEST® to the European Commission.
Pharming enters the Euronext Amsterdam Midkap-index (AMX)
Financial updatesPharming Group N.V. announces that it has been included in the Euronext Amsterdam Midkap index (AMX).